Iobenguane I-123

RADIATION2 trials

Sponsors

Children's Oncology Group

Conditions

GanglioneuroblastomaGanglioneuroblastoma, NodularNeuroblastoma

Phase 2

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Active, not recruitingNCT04385277

Children's Oncology GroupGanglioneuroblastoma, Nodular, Neuroblastoma

Start: 2020-12-31End: 2027-09-30Updated: 2025-10-27

Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

RecruitingNCT03126916

Children's Oncology GroupGanglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma

Start: 2018-05-14End: 2030-09-30Target: 750Updated: 2026-02-27

Related Papers

Abstract A037 Changes in T-cell repertoire during high-risk neuroblastoma therapy: A report from the Children’s Oncology Group

Cancer Research2024-09-05

A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.

Journal of Clinical Oncology2024-06-012 citations

Inequitable Poverty Exposures: A Subspecialty Opportunity to Address Disparities

Hospital Pediatrics2024-01-195 citations

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

Journal of Clinical Oncology2023-06-016 citations

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

Nature Communications2023-05-0540 citations

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Nature Medicine2023-04-03111 citations

A Structural Racism Framework to Guide Health Equity Interventions in Pediatric Oncology

PEDIATRICS2022-04-0712 citations

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

Frontiers in Pediatrics2022-03-1026 citations

A safety and feasibility trial of <sup>131</sup>I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study

Pediatric Blood & Cancer2021-05-2437 citations